Semaglutide

Extended indication	Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2.
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Semaglutide
Domain	Metabolism and Endocrinology
Reason of inclusion	Indication extension
Main indication	Other metabolism and Endocrinology
Extended indication	Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2.
Proprietary name	Wegovy
Manufacturer	Novo Nordisk
Mechanism of action	GLP-1 receptor agonist
Route of administration	Subcutaneous
Therapeutical formulation	Injection

Type of trajectory	Normal trajectory
Submission date	October 2023
Expected Registration	August 2024
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.